ImageVerifierCode 换一换
格式:PPT , 页数:25 ,大小:1.38MB ,
资源ID:216166      下载积分:6 文钱
快捷下载
登录下载
邮箱/手机:
温馨提示:
快捷下载时,用户名和密码都是您填写的邮箱或者手机号,方便查询和重复下载(系统自动生成)。 如填写123,账号就是123,密码也是123。
特别说明:
请自助下载,系统不会自动发送文件的哦; 如果您已付费,想二次下载,请登录后访问:我的下载记录
支付方式: 支付宝    微信支付   
验证码:   换一换

加入VIP,省得不是一点点
 

温馨提示:由于个人手机设置不同,如果发现不能下载,请复制以下地址【https://www.wenke99.com/d-216166.html】到电脑端继续下载(重复下载不扣费)。

已注册用户请登录:
账号:
密码:
验证码:   换一换
  忘记密码?
三方登录: QQ登录   微博登录 

下载须知

1: 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。
2: 试题试卷类文档,如果标题没有明确说明有答案则都视为没有答案,请知晓。
3: 文件的所有权益归上传用户所有。
4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
5. 本站仅提供交流平台,并不能对任何下载内容负责。
6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。

版权提示 | 免责声明

本文(阿伯西普联合以氟尿嘧啶为基础的化疗治疗晚期大肠癌的研究.ppt)为本站会员(h****)主动上传,文客久久仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对上载内容本身不做任何修改或编辑。 若此文所含内容侵犯了您的版权或隐私,请立即通知文客久久(发送邮件至hr@wenke99.com或直接QQ联系客服),我们立即给予删除!

阿伯西普联合以氟尿嘧啶为基础的化疗治疗晚期大肠癌的研究.ppt

1、读书报告,汇报人:罗娜,1,BACKGROUND,2,PATIENTSAND METHODS,3,RESULTS,4,CONCLUSIONS,Background,Patients with metastatic colorectal cancer (mCRC) previously-treated with oxaliplatin benefit significantly from the addition of aflibercept to FOLFIRI in relation to overall survival, progression-free survival and res

2、ponse rate.,1,01,typically regimen,02,FOLFOX+bevacizumab,03,FOLFIRI+aflibercept,04,Aflibercept,Background,typically regimen,Treatment of metastatic colorectal cancer (mCRC) typically involves a fluoropyrimidine-based hemotherapy regimen, combining infusional fluorouracil (5-FU) and leucovorin with o

3、xaliplatin (FOLFOX regimen) or rinotecan (FOLFIRI regimen).,1 Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22(1)

4、:2330.2 Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343(13):90514.3 Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cance

5、r: a randomized GERCOR study. J Clin Oncol 2004;22(2):22937.,FOLFOX+bevacizumab,In the E3200 study, it was shown that the addition of bevacizumab to FOLFOX improves survival duration for patients with previously treated mCRC who had not received first-line treatment with oxaliplatin or bev-acizumab.

6、,Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25(12):153944.,FOLFIRI+aflibercep

7、t,VEGF Trap (aflibercept) with irinotecan in colorectal cancer after failure of oxaliplatin regimen (VELOUR) was the first randomised, placebo-controlled, phase III trial to show a statistically significant improvement in OS, progression-free survival (PFS) and response rate (RR) for an anti-angioge

8、nic in combination with FOLFIRI compared with FOLFIRI alone in a prior oxaliplatin-treated population.,Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorec

9、tal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 2012;30(28):3499506.,FOLFIRI+aflibercept,Patients receiving FOLFIRI plus aflibercept had a median OS of 13.5 months versus 12.0 months for patients receiving FOLFIRI plus placebo, representing a relative reduction in the r

10、isk of death of 18.3% for the aflibercept arm compared with the placebo arm.,Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously trea

11、ted with an oxaliplatin-based regimen. J Clin Oncol 2012;30(28):3499506.,编译自:Aflibercept Approved for Colorectal Cancer in the US.Medscape.2012.8.3,阿柏西普是一种血管生成抑制剂,一种重组人融合蛋白,与循环VEGF紧密结合,使其不能与细胞表面受体相互作用,从而抑制血管内皮生长,比目前可用的抗血管生成药物如贝伐珠单抗有更广泛的作用机制。 2012年8月3日,FDA批准阿柏西普(Zaltrap,Regeneron/赛诺菲)治疗转移性结直肠癌。 3期VEL

12、OUR(阿柏西普vs安慰剂治疗奥沙利铂方案失败的转移性结直肠癌病人)试验的结果。在1226名病人中,阿柏西普添加到FOLFIRI方案中可显著改善总生存期和无进展生存期。 VELOUR临床试验的结果首次公布是在2011年的世界胃肠肿瘤大会上。阿柏西普的添加使反应率翻倍,从10%上升到20%。无进展生存期提高了23个月,最重要的是,总生存期从12.0个月上升到13.5个月。后续FDA发布的新闻稿中又增加了临床试验的细节:FOLFIRI方案单独治疗中位无进展生存期为4.7个月,添加阿柏西普上升到了6.9个月。,Aflibercept,Patientsand Methods,The results f

13、or efficacy and safety over the time course of the VEGF Trap (aflibercept) with irinotecan in colorectal cancer after failure of oxaliplatin regimen trial were analysed based on data from 1226 patients randomised to receive FOLFIRI plus either aflibercept (n = 612) or placebo (n = 614). Hazard ratio

14、s (HR) by 6-month time period were estimated using a piecewise Cox proportional hazard model. Severity of adverse events (AEs) was graded using National Cancer Institute Common Terminology Criteria, version 3.0.,2,Fig. 1. CONSORT chart.,Results,The estimated probabilities of survival were 38.5% vers

15、us 30.9% at 18 months, 28.0% versus 18.7% at 24 months and 22.3% versus 12.0% at 30 months, for the aflibercept-and placebo-treated arms, respectively. The proportional improvement in the HR over time was consistent with the survival probability results; survival at 24 months was improved by 50% and

16、 almost doubled at 30 months.,一、,3,1,Fig.2,Efficacy,Efficacy,Results,The majority of worst-grade AEs occurred within the first four cycles of treatment and in a small percent of treatment cycles and were mostly reversible. Common chemotherapy and anti-vascular epithelial growth factor (VEGF)associat

17、ed AEs occurred rarely and in a small proportion of cycles with the majority being of single occurrence.,3,2,Safety,Fig.3 Occurrence of selected anti-vascular epithelial growth factor (VEGF) and chemotherapy-related grade 34 adverse events (AEs) over the course of VELOUR. AFLI, aflibercept; PBO, pla

18、cebo.,Safety,Safety,Fig.4,Fig.4,Safety,Cycle of Worst Occurrence of Anti-VEGF- related and chemotherapy-related AEs,Grade 3/4,Fig.4,Safety,Fig.4,Safety,Conclusion,4,1,2,The addition of aflibercept to FOLFIRI showed a continued and persistent improvement in overall survival over time in patients with mCRC.,Although grade 34 AEs were more frequent in the aflibercept arm, they occurred in early treatment cycles and decreased sharply following initial presentation.,谢,谢,大,家,

Copyright © 2018-2021 Wenke99.com All rights reserved

工信部备案号浙ICP备20026746号-2  

公安局备案号:浙公网安备33038302330469号

本站为C2C交文档易平台,即用户上传的文档直接卖给下载用户,本站只是网络服务中间平台,所有原创文档下载所得归上传人所有,若您发现上传作品侵犯了您的权利,请立刻联系网站客服并提供证据,平台将在3个工作日内予以改正。